Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

7 April 2014

Swiss drug major Roche (ROG: SIX) has entered to a worldwide collaboration with Spanish functional genomics firm Oryzon Genomics to research, develop and commercialize inhibitors of lysine specific demethylase-1 (LSD1; KDM1A), an epigenetic modulator that regulates gene expression.

Under the terms of the accord, Oryzon will get an upfront payment and near-term milestones totalling $21 million, plus potential development, commercial and sales milestones across hematology, cancer and non-malignant indications that could exceed $500 million, together with tiered royalties on sales which range up to mid-double digits, said Roche.

Lead agent ORY-1001 currently in Phase I/IIa study in AML

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK